This medical non-promotional satellite symposium was organized and funded by Merck KGaA, Darmstadt, Germany, and intended for healthcare professionals (HCP) involved in treatment of colorectal cancer.
Optimizing 1L therapy in RAS wt mCRC: a wealth of evidence
Moving forward: The evolving treatment landscape for BRAF V600E mt mCRC
Expanding treatment horizons: Advancements in key mCRC populations
The following topics were covered during a symposium at the 2025 European Society for Medical Oncology Gastrointestinal Cancers (ESMO-GI) Congress:
- Optimising 1L therapy in RAS wild-type (wt) metastatic colorectal cancer (mCRC) with the overview of the ESMO guidelines and evidence for the benefits of anti-EGFR treatment in left-sided mCRC, as well as the challenges and current and emerging options for treatment in right-sided mCRC.
- The evolving treatment landscape for BRAF mt mCRC patients, highlighting the new data in the first line, changes in standards of care, as well as the ongoing trials.
- Exploring novel treatment strategies in mCRC, including data for inhibitors of MAPK signaling pathway, immunotherapies, antibody–drug conjugates, and modulators of DNA metabolism.
Speakers
Sebastian Stintzing1
Clara Montagut2
Erika Martinelli3
1. Charité – Universitätsmedizin Berlin, Germany
2. Hospital del Mar Research Institute, Barcelona, Spain
3. Department of Precision Medicine, Oncology Unit, Università della Campania “L. Vanvitelli”, Naples, Italy